Verastem Oncology granted fast track designation for VS-7375 for the treatment of KRAS G12D mutated locally advanced or metastatic pancreatic cancer

24 July 2025 - Enrollment is on-going in US Phase 1/2a trial for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, ...

Read more →

Solid Biosciences receives FDA fast track designation for SGT-501 first in class gene therapy for catecholaminergic polymorphic ventricular tachycardia

23 July 2025 - SGT-501 has now received FDA fast track, orphan drug and rare paediatric disease designations. ...

Read more →

DualityBio's next generation HER3 ADC DB-1310 granted FDA fast track designation

21 July 2025 - DualityBio announced that the US FDA has granted fast track designation to its next-generation HER3 targeting antibody ...

Read more →

ProMIS Neurosciences granted fast track designation by US FDA for PMN310 in the treatment of Alzheimer’s disease

21 July 2025 -  ProMIS Neurosciences today announced that the US FDA has granted fast track designation to PMN310, the ...

Read more →

Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

16 July 2025 -  The US FDA has granted fast track designation to SAR446597, a one-time intravitreal gene therapy for ...

Read more →

FDA grants Zenith’s ZEN-3694 fast track status

14 July 2025 - Zenith Epigenetics is pleased to announce the designation of ZEN-3694 as a fast track product by the ...

Read more →

FDA grants fast track designation for TRE-515 in combination with radiation therapy for the treatment of metastatic castration resistant prostate cancer

9 July 2025 - Trethera announced today that the US FDA has granted fast track designation for its novel drug, TRE-515, ...

Read more →

Vitalgen's gene therapy drug VGN-R09b for primary Parkinson's disease receives FDA fast track designation

26 June 2025 - Shanghai Vitalgen announced that its gene therapy drug, VGN-R09b, for the treatment of primary Parkinson’s disease, has ...

Read more →

Minovia Therapeutics announces FDA fast track and rare paediatric disease designations for MNV-201 in Pearson syndrome

30 June 2025 - Minovia Therapeutics announces that the US FDA has granted fast track designation to the Company’s lead investigational ...

Read more →

Schrödinger receives fast track designation for SGR-1505 for the treatment of relapsed/refractory Waldenström's macroglobulinemia

27 June 2025 - Demonstrates the potential of SGR-1505 as a novel approach for diseases with high unmet medical need. ...

Read more →

Duke Street Bio receives FDA fast track designation for DSB2455

10 June 2025 - Duke Street Bio today announced that the US FDA has granted fast track designation to DSB2455, its ...

Read more →

BioAegis Therapeutics receives FDA fast track designation for lead product, recombinant human gelsolin, for the treatment of acute respiratory distress syndrome

17 June 2025 - BioAegis Therapeutics announces that the US FDA has granted fast track designation to its lead product candidate, ...

Read more →

Tisento Therapeutics receives US FDA fast track designation for zagociguat for the treatment of MELA

17 June 2025 - Global Phase 2b PRIZM study of zagociguat is currently enrolling participants with MELAS. ...

Read more →

Ferrer receives FDA fast track designation for FNP-223 in progressive supranuclear palsy

17 June 2025 - Ferrer has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development ...

Read more →

SolasCure receives FDA fast track designation for Aurase wound gel to treat calciphylaxis ulcers

16 June 2025 - Solascure today announced that the US FDA has granted fast track designation for its investigational Aurase wound ...

Read more →